Immune Response to COVID-19 Vaccine Different with Prior Infection
Retrieved on:
Tuesday, October 12, 2021
Sandler Foundation, Technology, Pfizer–BioNTech COVID-19 vaccine, Infection, Program, George Mason University, ELife, Doctor of Philosophy, Antibody, SAN, Victoria, CyTOF, COVID-19, Cell, Protein, University of California, Moore v. Regents of the University of California, Multimedia, Mercatus Center, Immunization, Award, UC, University of California, San Francisco, Fast Grants, Pfizer, Vaccination, University, Roan, Immune system, United Kingdom, Longevity, Vaccine, Biomedical Research, RNA transfection, Gladstone Institutes, Arm, Severe acute respiratory syndrome coronavirus 2, Media contacts database, Communication, Urology, View, Pharmaceutical industry
Antibodies produced by the immune system's B cells can quickly recognize a virus, target it for destruction, and prevent infection.
Key Points:
- Antibodies produced by the immune system's B cells can quickly recognize a virus, target it for destruction, and prevent infection.
- While antibodies are more effective at stopping initial infection completely, T cells generally last longer after an initial infection or vaccine and can help quell disease in its early stages, preventing severe symptoms.
- Distinct subsets of T cells respond differently to infected cells and have different functions within the overall T cell response.
- However, in those who had previously had a COVID-19 infection, there was little change between the first and second dose of the vaccine.